-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the reform of the national drug review and approval system, the injection of a large amount of high-quality capital is bringing more and more development momentum to the Chinese pharmaceutical industry
.
At the same time, a large number of pharmaceutical companies have also begun to improve their innovative research and development capabilities, and thus have incubated a large number of Chinese innovative companies and products
.
According to data, in 2021, China's National Medical Products Administration (NMPA) has approved 76 new drugs (excluding new indications and vaccines) for the market, including cyclopofol injection, ainovirine tablets, and savatinib tablets.
, Levoornidazole disodium phosphate for injection and other blockbuster drugs, these drugs involve tumors, vaccines, rare diseases and other fields
.
Domestic innovative drugs usher in a blowout period (Photo source: Pharmaceutical Network) Overall, the development of local new drugs is different from the past
.
It is worth noting that behind the rapid increase in the number of new drug approvals and the blowout period of innovative achievements, analysts believe that these two major areas will become the main driving force for the emergence of innovative drugs, and they are worthy of focus in the future
.
Antineoplastic Drugs Under the background of the continuous increase in the number of cancer patients, the continuous improvement of medical level, and the escalating consumption, the market demand for antineoplastic drugs is growing
.
The huge market prospects will naturally attract more and more pharmaceutical companies to enter the market, and more innovative achievements will appear
.
It is understood that the number of innovative research and development of oncology drugs by domestic pharmaceutical companies has been increasing
.
According to data, by the end of 2021, at least 30 new drugs have been approved for marketing through priority review, and the majority of them are oncology drugs and rare disease drugs
.
Among the new drugs approved, 13 are new oncology drugs, covering non-small cell lung cancer, large B cell lymphoma, breast cancer, hepatocellular carcinoma, gastric cancer, ovarian cancer, fallopian tube cancer or primary peritoneal cancer, basal cell carcinoma and other fields
.
It can be seen that tumor drugs are still the long-term main line of domestic drug innovation
.
However, it should be noted that with the continuous intensification of entrants, the competition in this field is also becoming more and more fierce.
.
According to data, as of January 6, 2022, the total number of global clinical trials of the popular target PD-1 has reached 3,471, of which China (CDE registration) is 675, accounting for about 19.
5% of the world
.
Traditional Chinese Medicine With the continuous release of favorable national policies, innovative traditional Chinese medicine drugs have also achieved rapid development as a part of the traditional Chinese medicine industry
.
In 2021, under the reform of the Chinese medicine review and approval system, a total of 11 innovative Chinese medicines have been approved for marketing, including Yinqiao Qingre Tablets, Xuanqijiangu Tablets, Qizhi Yishen Capsules, Kunxinning Granules, and Qingfei Paidu Granules.
, Huashibaidu Granules, Xuanfeibaidu Granules, Yishen Yangxin Anshen Tablets and Yiqi Tongqiao Pills, etc.
, hit a new high in the past five years
.
In 2022, the industry has ushered in the news of the approval and marketing of innovative traditional Chinese medicines such as Huzhen Qingfeng Capsule and Jieyu Chufan Capsule
.
In this regard, the industry believes that with the support of favorable policies and the continuous investment of traditional Chinese medicine companies in the field of innovation in the future, the approval and marketing of new traditional Chinese medicines will be accelerated, and it is likely that there will be more than 20 per year
.
Conclusion In recent years, with the multiple resonances of policies, capital, and talents, China's local innovative drugs have flourished, and the enthusiasm of enterprises for research and development has been high, and batches of self-developed new drugs have begun to emerge
.
However, behind the continuous emergence of innovative achievements, pharmaceutical companies need to clearly realize that the research and development of innovative drugs is not a smooth road, and the risks involved are also worthy of vigilance
.
.
At the same time, a large number of pharmaceutical companies have also begun to improve their innovative research and development capabilities, and thus have incubated a large number of Chinese innovative companies and products
.
According to data, in 2021, China's National Medical Products Administration (NMPA) has approved 76 new drugs (excluding new indications and vaccines) for the market, including cyclopofol injection, ainovirine tablets, and savatinib tablets.
, Levoornidazole disodium phosphate for injection and other blockbuster drugs, these drugs involve tumors, vaccines, rare diseases and other fields
.
Domestic innovative drugs usher in a blowout period (Photo source: Pharmaceutical Network) Overall, the development of local new drugs is different from the past
.
It is worth noting that behind the rapid increase in the number of new drug approvals and the blowout period of innovative achievements, analysts believe that these two major areas will become the main driving force for the emergence of innovative drugs, and they are worthy of focus in the future
.
Antineoplastic Drugs Under the background of the continuous increase in the number of cancer patients, the continuous improvement of medical level, and the escalating consumption, the market demand for antineoplastic drugs is growing
.
The huge market prospects will naturally attract more and more pharmaceutical companies to enter the market, and more innovative achievements will appear
.
It is understood that the number of innovative research and development of oncology drugs by domestic pharmaceutical companies has been increasing
.
According to data, by the end of 2021, at least 30 new drugs have been approved for marketing through priority review, and the majority of them are oncology drugs and rare disease drugs
.
Among the new drugs approved, 13 are new oncology drugs, covering non-small cell lung cancer, large B cell lymphoma, breast cancer, hepatocellular carcinoma, gastric cancer, ovarian cancer, fallopian tube cancer or primary peritoneal cancer, basal cell carcinoma and other fields
.
It can be seen that tumor drugs are still the long-term main line of domestic drug innovation
.
However, it should be noted that with the continuous intensification of entrants, the competition in this field is also becoming more and more fierce.
.
According to data, as of January 6, 2022, the total number of global clinical trials of the popular target PD-1 has reached 3,471, of which China (CDE registration) is 675, accounting for about 19.
5% of the world
.
Traditional Chinese Medicine With the continuous release of favorable national policies, innovative traditional Chinese medicine drugs have also achieved rapid development as a part of the traditional Chinese medicine industry
.
In 2021, under the reform of the Chinese medicine review and approval system, a total of 11 innovative Chinese medicines have been approved for marketing, including Yinqiao Qingre Tablets, Xuanqijiangu Tablets, Qizhi Yishen Capsules, Kunxinning Granules, and Qingfei Paidu Granules.
, Huashibaidu Granules, Xuanfeibaidu Granules, Yishen Yangxin Anshen Tablets and Yiqi Tongqiao Pills, etc.
, hit a new high in the past five years
.
In 2022, the industry has ushered in the news of the approval and marketing of innovative traditional Chinese medicines such as Huzhen Qingfeng Capsule and Jieyu Chufan Capsule
.
In this regard, the industry believes that with the support of favorable policies and the continuous investment of traditional Chinese medicine companies in the field of innovation in the future, the approval and marketing of new traditional Chinese medicines will be accelerated, and it is likely that there will be more than 20 per year
.
Conclusion In recent years, with the multiple resonances of policies, capital, and talents, China's local innovative drugs have flourished, and the enthusiasm of enterprises for research and development has been high, and batches of self-developed new drugs have begun to emerge
.
However, behind the continuous emergence of innovative achievements, pharmaceutical companies need to clearly realize that the research and development of innovative drugs is not a smooth road, and the risks involved are also worthy of vigilance
.
